About BGI
BGI is a company based in Shenzhen (China) founded in 1999. It operates as a HealthTech and Professional Services. The company has 3,700 employees as of December 31, 2024. BGI offers products and services including NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis. BGI operates in a competitive market with competitors including Novogene Corporation, Rejuvenate Bio, Source BioScience, Beikang Medical and Macrogen, among others.
- Headquarter Shenzhen, China
- Employees 3700 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bgi Genomics Co. Ltd. Class A
-
Annual Revenue
$527.44 M (USD)-11.27as on Dec 31, 2024
-
Net Profit
-$123.67 M (USD)-1071.68as on Dec 31, 2024
-
EBITDA
-$18.09 M (USD)-122.67as on Dec 31, 2024
-
Latest Funding Round
$300 M (USD), Post-IPO
Feb 22, 2021
-
Investors
SDIC
& 1 more
-
Employee Count
3700
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BGI
BGI is a publicly listed company on the SZSE with ticker symbol 300676 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BGI
BGI offers a comprehensive portfolio of products and services, including NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis.
Non-invasive prenatal testing for single-gene disorders offered.
Genetic testing for late-stage tumor survival solutions.
Genomic solutions for rare disease diagnosis provided.
People of BGI
Unlock access to complete
Sales and Marketing
12 people
Board Team
7 people
Human Resources and Administration
6 people
Product Management Team
5 people
Independent Team
4 people
Software Development Team
4 people
Supervisor Team
2 people
Field Team
2 people
Unlock access to complete
Funding Insights of BGI
Investors in BGI
BGI has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include SDIC and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment holding company
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for BGI
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BGI
Investment portfolio details for BGI
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BGI
Detailed financials for BGI
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bgi Comparisons
Peer comparison for BGI
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BGI
BGI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novogene Corporation, Rejuvenate Bio, Source BioScience, Beikang Medical and Macrogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
Gene-editing platform and anti-aging therapy for dogs are developed.
|
|
| Locked | Locked | Locked |
Multiple genomic services are provided for analysis and diagnostics.
|
|
| Locked | Locked | Locked |
NGS-based diagnostic solutions for neonatal screening are developed.
|
|
| Locked | Locked | Locked |
Next-generation sequencing and genomics services are provided globally.
|
|
| Locked | Locked | Locked |
Genome sequencing, analysis, and genetic screening services are provided.
|
Detailed competitors of BGI
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bgi
Complete news archive for BGI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BGI
BGI was founded in 1999 and raised its 1st funding round 16 years after it was founded.
BGI is headquartered in Shenzhen, China. It is registered at Shenzhen, Guangdong, China.
Wang Jian is the current CEO of BGI.
As of Dec 31, 2024, the latest employee count at BGI is 3,700.
Annual revenue of BGI is $527.44M as on Dec 31, 2024.
BGI, based in Shenzhen, China, is focused on advancing life sciences through genomics and precision medicine. The company is involved in genetic testing, oncology solutions, and rare disease diagnosis. Services are provided across maternal and child health, tumor prevention, infectious disease control, and chronic disease management. Operations span multiple regions in China, integrating clinical, research, and public health initiatives to enhance healthcare outcomes. BGI is committed to reducing birth defects and improving global health standards through innovative technologies.
BGI's top competitors include Novogene Corporation, Source BioScience and Genewiz.
BGI offers NIFTY®200+, Liver and Pancreatic Tumor Testing, and Rare Disease Genomic Diagnosis.
Yes, BGI is publicly traded on SZSE under the ticker symbol 300676.
BGI has 2 investors. Key investors include SDIC, and European Union.
The ticker symbol of BGI is 300676 on SZSE.